Biochemical Markers of Bone Metabolism

Pediatric Bone: Biology & Diseases

Volumn , Issue , 2003, Pages 339-357

  Schönau, Eckhard ^a   Rauch, Frank ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24844436778     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012286551-0/50016-6     Document Type: Chapter

References (147)

1. Acil Y., Brinckmann J., Notbohm H., Muller P.K., Batge B. Changes with age in the urinary excretion of hydroxyly-sylpyridinoline and lysylpyridinoline (LP). Scand. J. Clin. Lab. Invest. 1996, 56:275-283.
2. Allison D.J., Walker A., Smith Q.T. Urinary hydro-xyproline: Creatinine ratio of normal humans at various ages. Clin. Chim. Acta 1966, 14:729-734.
3. Baron R.E. Anatomy and ultrastructure of bone. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1996, 3-10. Lippincott-Raven, Cambridge, UK. 3rd ed. M.J. Favus (Ed.).
4. Baroncelli G.I., Bertelloni S., Ceccarelli C., Amato V., Saggese G. Bone turnover in children with vitamin D deficiency rickets before and during treatment. Acta Paediatr. 2000, 89:513-518.
5. Bishop N. Bone disease in preterm infants. Arch. Dis. Child. 1989, 64:1403-1409.
6. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatog-raphy. Anal. Biochem. 1988, 169:197-203.
7. Blumsohn A., Hannon R.A., Wrate R., Barton J., Al-Dehaimi A.W., Colwell A., Eastell R. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 1994, 40:663-670.
8. Bollen A.M., Eyre D.R. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994, 15:31-34.
9. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 1994, 40:2022-2025.
10. Branca F., Robins S.P., Ferro-Luzzi A., Golden M.H. Bone turnover in malnourished children. Lancet 1992, 340:493-1496.
11. Brenner R.E., Schiller B., Vetter U., Ittner J., Teller W.M. Serum concentrations of procollagen I C-terminal pro-peptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr. 1993, 82:764-767.
12. Brenner R.E., Vetter U., Bollen A.M., Morike M., Eyre D.R. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J.Bone Miner. Res. 1994, 9:993-997.
13. Calvo M.S., Eyre D.R., Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 1996, 17:333-368.
14. Clark L.C., Beck E. Plasma "alkaline" phosphatase activity. I. Normative data for growing children. J.Pediatr. 1949, 335-341.
15. Clemens J.D., Herrick M.V., Singer F.R., Eyre D.R. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997, 43:2058-2063.
16. Coen G., Mazzaferro S., Ballanti P., Bonucci E., Bondatti F., Manni M., Pasquali M., Perruzza I., Sardella D., Spurio A. Procollagen type I C-terminal extension peptide in predia-lysis chronic renal failure. Am. J. Nephrol. 1992, 12:246-251.
17. Cole D.E., Carpenter T.O., Gundberg C.M. Serum osteocalcin concentrations in children with metabolic bone disease. J.Pediatr. 1985, 196:770-776.
18. Colwell A., Eastell R. The renal clearance of free and conjugated pyridinium cross-links of collagen. J.Bone Miner. Res. 1996, 11:1976-1980.
19. Crofton P.M. Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: Age-dependent reference ranges and changes in liver and bone disease. Clin. Chem. 1992, 38:663-670.
20. Crofton P.M., Ahmed S.F., Wade J.C., Elmlinger M.W., Ranke M.B., Kelnar C.J., Wallace W.H. Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term grow. Eur. J. Cancer 1999, 35:960-967.
21. Crofton P.M., Ahmed S.F., Wade J.C., Elmlinger M.W., Ranke M.B., Kelnar C.J., Wallace W.H. Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr. Res. 2000, 48:490-496.
22. Crofton P.M., Ahmed S.F., Wade J.C., Stephen R., Elmlinger M.W., Ranke M.B., Kelnar C.J., Wallace W.H. Effects of intensive chemotherapy on bone and collagen turnover and growth hormone axis in children with acute lymphoblastic leukemia. J.Clin. Endocrinol. Metab. 1998, 83:3121-3129.
23. Crofton P.M., Hume R. Alkaline phosphatase isoen-zymes in the plasma of preterm and term infants: Serial measurements and clinical correlations. Clin. Chem. 1987, 33:1783-1787.
24. Crofton P.M., Shrivastava A., Wade J.C., Stephen R., Kelnar C.J.H., Mclntosh N., Lyon A.J. Effects of dexa-methasone treatment on bone and collagen turnover in preterm infants with chronic lung disease. Pediatr. Res. 2000, 48:155-162.
25. Crofton P.M., Stirling H.F., Kelnar C.J. Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: Longitudinal study. Clin. Chem. 1995, 41:672-678.
26. Crofton P.M., Stirling H.F., Schonau E., Kelnar C.J. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin. Endocrinol. 1996, 44:385-394.
27. Crofton P.M., Wade J.C., Taylor M.R., Holland C.V. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal. Clin. Chem. 1997, 43:1577-1581.
28. De Zegher F., Maes M., Gargosky S.E., Heinrichs C., Caju M.V.D., Thiry G., De Schepper J., Craen M., Breysem L., Löf-Strom A., Jönsson P., Bourgingnon J.P., Malvaux P., Rosenfeld R.G. High-dose growth hormone treatment of short children born small for gestational age. J.Clin. Endocrinol Metab. 1996, 81:1887-1892.
29. Delmas P.D., Glorieux F.H., Delvin E.E., Salle B.L., Melki I. Perinatal serum bone Gla-protein and vitamin D metabolites in preterm and full-term neonates. J.Clin. Endocrinol. Metab. 1987, 65:588-591.
30. Demarini S., Specker B.L., Sierra R.I., Miodovnik M., Tsang R.C. Evidence of increased intrauterine bone resorption in term infants of mothers with insulin-dependent diabetes. J.Pediatr. 1995, 126:796-798.
31. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., Smith E., Bonadio J., Goldstein S., Gundberg C., Bradley A., Karsenty G. Increased bone formation in osteo-calcin-deficient mice. Nature 1996, 382:448-452.
32. Dunn P.M. A perinatal growth chart for international reference. Acta Paediatr. Scand. Suppl. 1985, 319:180-187.
33. Eyre D.R., Paz M.A., Gallop P.M. Cross-linking in collagen and elastin. Annu. Rev. Biochem. 1984, 53:717-748.
34. Fewtrell M.S., Cole T.J., Bishop N.J., Lucas A. Neonatal factors predicting childhood height in preterm infants: Evidence for a persisting effect of early metabolic bone disease?. J.Pediatr. 2000, 137:668-673.
35. Frost H.M. Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's law: The bone modeling problem. Anat. Rec. 1990, 226:403-413.
36. Frost H.M. Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolffs law: The remodeling problem. Anat. Rec. 1990, 226:414-422.
37. Fujimoto S., Kubo T., Tanaka H., Miura M., Seino Y. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J.Clin. Endocrinol. Metab. 1995, 80:1922-1928.
38. Garn S.M. The course of bone gain and the phases of bone loss. Orthop. Clin. North Am. 1972, 3:503-520.
39. Greig F., Casas J., Castells S. Changes in plasma osteocalcin concentrations during treatment of rickets. J.Pediatr. 1989, 114:820-833.
40. Halleen J., Hentunen T.A., Hellman J., Vaananen H.K. Tartrate-resistant acid phosphatase from human bone: Purification and development of an immunoassay. J.Bone Miner. Res. 1996, 11:1444-1452.
41. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Vaananen H.K. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J.Bone Miner. Res. 2000, 15:1337-1345.
42. Halton J.M., Atkinson S.A., Fraher L., Webber C., Gill G.J., Dawson S., Barr R.D. Altered mineral metabolism and bone mass in children during treatment acute lymphoblastic leukemia. J.Bone Miner. Res. 1996, 11:1774-1783.
43. Harrast S.D., Kalkwarf H.J. Effects of gestational age, maternal diabetes, and intrauterine growth retardation on markers of fetal bone turnover in amniotic fluid. Calcif. Tissue Int. 1998, 62:205-208.
44. Hertel N.T., Stoltenberg M., Juul A., Main K.M., Muller J., Nielsen C.T., Lorenzen I., Skakkebaek N.E. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropi. J.Clin. Endocrinol. Metab. 1993, 76:924-927.
45. Heuck C., Heickendorff L., Wolthers O.D. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch. Dis. Child 2000, 83:334-339.
46. Heuck C., Skjaerbaek C., Wolthers O.D. Diurnal rhythm of serum osteocalcin in normal children. Acta Paediatr. 1998, 87:930-932.
47. Heymsfield S.B., Arteaga C., Mcmanus C., Smith J., Moffitt S. Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method. Am. J. Clin. Nutr. 1983, 37:478-494.
48. Hillman L., Schlotzhauer C., Lee D., Grasela J., Witter S., Allen S., Hillman R. Decreased bone mineralization in children with phenylketonuria under treatment. Eur. J. Pediatr. 1996, 155(Suppl. 1):S148-S152.
49. Hruska K.A., Teitelbaum S.L. Renal osteodystrophy. N.Engl. J. Med. 1995, 333:166-174.
50. Husain S.M., Mughal Z., Williams G., Ward K., Smith C.S., Dutton J., Fraser W.D. Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds. Arch. Dis. Child. 1999, 80:370-373.
51. Hyams J.S., Moore R.E., Leichtner A.M., Carey D.E., Goldberg B.D. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J.Pediatr. 1988, 112:893-898.
52. Hyams J.S., Moore R.E., Leichtner A.M., Carey D.E., Goldberg B.D. Longitudinal assessment of type I procol-lagen in children with inflammatory bowel disease subjected to surgery. J.Pediatr. Gastroenterol. Nutr. 1989, 8:68-74.
53. Hytinantti T., Rutanen E.M., Turpeinen M., Sorva R., Andersson S. Markers of collagen metabolism and insulin-like growth factor binding protein-1 in term infants. Arch. Dis. Child. 2000, 83:F17-F20.
54. Jensen L.T., Jorgensen J.O.L., Risteli J., Christiansen J.S., Lorenzen I. Type I and III procollagen propeptides in growth hormone-deficient patients: Effects of increasing doses of GH. Acta Endocrinol. 1991, 124:278-282.
55. Johansen J.S., Jensen S.B., Riis B.J., Rasmussen L., Zachmann M., Christiansen C. Serum bone gla protein: A potential marker of growth hormone (GH) deficiency and the response to GH therapy. J.Clin. Endocrinol. Metab. 1990, 71:122-126.
56. Kajantie E., Hytinantti T., Koistinen R., Risteli J., Rutanen E.M., Seppala M., Andersson S. Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: Relations. Pediatr. Res. 2001, 49:481-489.
57. Kanzaki S., Hosoda K., Moriwake T., Tanaka J., Kubo T., Inoue M., Higuchi J., Yamaji T., Seino Y. Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: A potential marker of bone growth and r. J.Clin. Endocrinol. Metab. 1992, 75:1104-1109.
58. Kauppila S., Tekay A., Risteli L., Koivisto M., Risteli J. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur. J. Clin. Invest. 1998, 28:831-837.
59. Klein G.L. Nutritional rickets and osteomalacia. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1996, 301-305. Raven Press, Philadelphia. M.J. Favus (Ed.).
60. Klein G.L., Herndon D.N., Goodman W.G., Langman C.B., Phillips W.A., Dickson I.R., Eastell R., Naylor K.E., Maloney N.A., Desai M., et al. Histomorphometric and biochem ical characterization of bone following acute severe burns in children. Bone 1995, 17:455-460.
61. Konig P., Hillman L., Cervantes C., Levine C., Maloney C., Douglass B., Johnson L., Allen S. Bone metabolism in children with asthma treated with inhaled beclomethasone dipro-pionate. J.Pediatr. 1993, 122:219-226.
62. Kovacs C.S., Kronenberg H.M. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr. Rev. 1997, 18:832-872.
63. Krane S.M., Kantrowitz F.G., Byrne M., Pinnell S.R., Singer F.R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J.Clin. Invest. 1977, 59:819-827.
64. Kruse K., Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur. J. Pediatr. 1986, 145:27-33.
65. Kubo T., Tanaka H., Inoue M., Kanzaki S., Seino Y. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal and children with growt. Bone 1995, 17:397-401.
66. Leigh S.D., Ju H.S., Lundgard R., Daniloff G.Y., Liu V. Development of an immunoassay for urinary galactosylhy droxylysine. J.Immunol. Methods 1998, 220:169-178.
67. Lieuw A.F.M., Sierra R.I., Specker B.L. Carboxy terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J.Bone Miner. Res. 1995, 10:849-853.
68. Loughead J.L., Mimouni F., Ross R., Tsang R.C. Postnatal changes in serum osteocalcin and parathyroid hormone concentrations. J.Am. Coll. Nutr. 1990, 9:358-362.
69. Lucas A., Brooke O.G., Baker B.A., Bishop N., Morley R. High alkaline phosphatase activity and growth in preterm neonates. Arch. Dis. Child. 1989, 64:902-909.
70. Lund A.M., Hansen M., Kollerup G., Juul A., Teisner B., Skovby F. Collagen-derived markers of bone metabolism in osteogenesis. Acta Paediatr. 1998, 87:1131-1137.
71. Lund A.M., Molgaard C., Muller J., Skovby F. Bone mineral content and collagen defects in osteogenesis imper-fecta. Acta Paediatr. 1999, 88:1083-1088.
72. Lutchman E.C., Hardwick T.A., Biener R., Chowdhury H.A., Trout J.R., Shapses S.A. Longitudinal study of urinary hydroxy-pyridinium cross-links and healthy infants: Higher values with breastfeeding and after daytime. Exp. Clin. Endocrinol. Diabetes 1998, 106:51-56.
73. Magnusson P., Larsson L., Magnusson M., Davie M.W., Sharp C.A. Isoforms of bone alkaline phosphatase: Characterization and origin in human trabecular and cortical bone. J.Bone Miner. Res. 1999, 14:1926-1933.
74. Marowska J., Kobylinska M., Lukaszkiewicz J., Talajko A., Rymkiewicz-Kluczynska B., Lorenc R.S. Pyridinium crosslinks of collagen as a marker of bone resorption rates children and adolescents: Normal values and clinical application. Bone 1996, 19:669-677.
75. Masters P.W., Jones R.G., Purves D.A., Cooper E.H., Cooney J.M. Commercial assays for serum osteocalcin give clinically discordant results. Clin. Chem. 1994, 40:358-363.
76. Matikainen T., Kakonen S.M., Pettersson K., Karp M., Lovgren T., Vaananen H., Hellman J. Demonstration of the predominant urine osteocalcin fragments detectable by two-site immunoassays. J.Bone Miner. Res. 1999, 14:431-438.
77. Melkko J., Hellevik T., Risteli L., Risteli J., Smedsrad B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J.Exp. Med. 1994, 179:405-412.
78. Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 1996, 42:947-954.
79. Melkko J., Niemi S., Risteli L., Risteli J. Radio-immunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 1990, 36:1328-1332.
80. Michaelsen K.F., Johansen J.S., Samuelson G., Price P.A., Christiansen C. Serum bone y-carboxyglutamic acid protein in a longitudinal study of infants: Lower values in formula-fed infants. Pediatr. Res. 1992, 31:401-405.
81. Mora S., Prinster C., Bellini A., Weber G., Proverbio M.C., Puzzovio M., Bianchi C., Chiumello G. Bone turnover in neonates: Changes of urinary excretion rate of collagen type I cross-linked peptides during the first days of life and influence of gestation. Bone 1997, 20:563-566.
82. Namgung R., Tsang R.C., Specker B.L., Sierra R.I., Ho M.L. Reduced serum osteocalcin and 1,25-dihydroxyvitamin D concentrations and low bone mineral content in small for gestational age infants: Evidence of decreased. J.Pediatr. 1993, 122:269-275.
83. Nava S., Bocconi L., Zuliani G., Kustermann A., Nicolini U. Aspects of fetal physiology from 18 to 37 weeks' gestation as assessed by blood sampling. Obstet. Gynecol 1996, 87:975-980.
84. Naylor K.E., Eastell R., Shattuck K.E., Alfrey A.C., Klein G.L. Bone turnover in preterm infants. Pediatr. Res. 1999, 45:363-366.
85. Nielsen H.K., Jorgensen O.L., Brixen K., Christiansen J.S. Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: Dose-response studies with biosynthetic human GH. Calcif. Tissue Int. 1991, 48:82-87.
86. Oginni L.M., Worsfold M., Sharp C.A., Oyelami O.A., Powell D.E., Davie M.W.J. Plasma osteocalcin in healthy Nigerian children and in children with calcium deficiency rickets. Calcif. Tissue Int. 1996, 59:424-427.
87. Ogueh O., Khastgir G., Studd J., Jones J., Alaghband-Zadeh J., Johnson M.R. Maternal and fetal plasma levels of markers of bone metabolism in gestational diabetic pregnancies. Early Hum. Dev. 1998, 53:155-161.
88. Ogueh O., Wright E.M., Jones J., Alaghband-Zadeh J., Nicolaides K.H., Johnson M.R. Fetal bone metabolism in normal and rhesus isoimmunised pregnancies. Bjog 2001, 108:986-992.
89. Parfitt A.M. Bone-forming cells in clinical conditions. The Osteoblast and Osteocyte 1990, 351-429. Telford, New York. B.K. Hall (Ed.).
90. Parfitt A.M., Travers R., Rauch F., Glorieux F.H. Structural and cellular changes during bone growth in healthy children. Bone 2000, 27:487-494.
91. Pasquali N., Still M.J., Dembure P.P., Elsas L.J. Pyridinium cross-links in heritable disorders of collagen [Letter]. Am. J. Hum. Genet. 1995, 57:1508-1510.
92. Pepmueller P.H., Cassidy J.T., Allen S.H., Hillman L.S. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1996, 39:746-757.
93. Pittard W.B.D., Geddes K.M., Hulsey T.C., Hollis B.W. Osteocalcin, skeletal alkaline phosphatase, and bone mineral content in very low birth weight infants: A longitudinal assessment. Pediatr. Res. 1992, 31:181-185.
94. Pratico G., Caltabiano L., D'agata A., Fichera A., Ras-Panti L. Normal serum levels of osteocalcin in the first 90 days of life. Riv. Ital. Pediatr. 1992, 18:410-413.
95. Pratico G., Caltabiano L., Palano G.M., Sciacca P., D'agata A. Normal levels of carboxyterminal propeptide of type I procollagen in the first three months of life. Pediatr. Med. Chir. 1995, 17:127-129.
96. Pratico G., Caltabiano L., Palano G.M., Zingale A. Normal levels of collagen-type-I telopeptide in the first 90 days of life. Pediatr. Med. Chir. 1998, 20:193-195.
97. Proszynska K., Wieczorek E., Olszaniecka M., Lorenc R.S. Collagen peptides in osteogenesis imperfecta, idiopathic juvenile osteoporosis and Ehlers-Danlos syndrome. Acta Paediatr. 1996, 85:688-691.
98. Rauch F., Georg M., Stabrey A., Neu C.M., Remer T., Manz F., Schoenau E. Collagen markers deoxypyridinoline and hydroxylysine glycosides: Pediatric reference data and use for growth prediction in growth hormone deficient children. Clin. Chem. 2002, 48:315-322.
99. Rauch F., Middelmann B., Cagnoli M., Keller K.M., Schonau E. Comparison of total alkaline phosphatase and three assays for bone-specific alkaline phosphatase in childhood and adolescence. Acta Paediatr. 1997, 86:583-587.
100. Rauch F., Schnabel D., Seibel M.J., Remer T., Stabrey A., Michalk D., Schonau E. Urinary excretion of galac-tosyl-hydroxylysine is a marker of growth in children. J.Clin. Endocrinol. Metab. 1995, 80:1295-1300.
101. Rauch F., Schoenau E. The developing bone: Slave or master of its cells and molecules?. Pediatr. Res. 2001, 50:309-314.
102. Rauch F., Schonau E., Woitge H., Remer T., Seibel M. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp. Clin. Endocrinol 1994, 102:94-97.
103. Rauch F., Travers R., Parfitt A.M., Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000, 26:581-589.
104. Reed A.M., Haugen M., Pachman L.M., Langman C.B. Repair of osteopenia in children with juvenile rheumatoid arthritis. J.Pediatr. 1993, 122:693-696.
105. Reiss I., Inderrieden D., Kruse K. Bestimmung der knochenspezifischen alkalischen Phosphatase bei Storungen des Kalziumstoffwechsels im Kindesalter. Monatsschr. Kinderheilkd. 1996, 144:885-890.
106. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-links car-boxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin. Chem. 1993, 39:635-640.
107. Rodin A., Duncan A., Quartero H.W., Pistofidis G., Mashiter G., Whitaker K., Crook D., Stevenson J.C., Chapman M.G., Fogelman I. Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J.Clin. Endocrinol. Metab. 1989, 68:1123-1127.
108. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telop. Clin. Chem. 1998, 44:2281-2289.
109. Saarela T., Risteli J., Kauppila A., Koivisto M. Effect of short-term antenatal dexamethasone administration on type I collagen synthesis and degradation in preterm infants at birth. Acta Paediatr. 2001, 90:921-925.
110. Saarela T., Risteli J., Kauppila A., Koivisto M. Type I collagen markers in cord serum of appropriate vs small for gestational age infants born during the second half of pregnancy. Eur. J. Clin. Invest. 2001, 31:438-443.
111. Saggese G., Baroncelli G.I., Bertelloni S., Cinquanta L., Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J.Pediatr. 1993, 122:37-45.
112. Saggese G., Baroncelli G.I., Bertelloni S., Cinquanta L., Di Nero G. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and gro. Pediatr. Res. 1994, 35:409-415.
113. Saggese G., Bertelloni S., Baroncelli G.I., Di Nero G. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur. J. Pediatr. 1992, 151:764-768.
114. Salusky I.B., Coburn J.W., Brill J., Foley J., Slatopolsky E., Fine R.N., Goodman W.G. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988, 33:975-982.
115. Salusky I.B., Ramirez J.A., Oppenheim W., Gales B., Segre G.V., Goodman W.G. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 1994, 45:253-258.
116. Sartorio A., Conti A., Guzzolani G., Faglia G. Serum osteocalcin levels in patients with GH deficiency before and during GH treatment. Acta Paediatr. Scand. 1991, 80:100-102.
117. Scariano J.K., Walter E.A., Glew R.H., Hollis B.W., Henry A., Ocheke I., Isichei C.O. Serum levels of the pyridinoline crosslinked carboxyterminal of type I collagen (ICTP) and osteocalcin in rachitic children. Clin. Biochem. 1995, 28:541-545.
118. Schoenau E., Westermann F., Rauch F., Stabrey A., Wassmer G., Keller E., Bramswig J., Blum W.F. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur. J. Endocrinol. 2001, 144:13-20.
119. Schonau E., Herzog K.H., Bohles H.J. Transient hyperphosphatasemia of infancy. Eur. J. Pediatr. 1988, 148:264-266.
120. Segrest J.P., Cunningham L.W. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J.Clin. Invest. 1970, 49:1497-1509.
121. Seibold-Weiger K., Wollmann H.A., Ranke M.B., Speer C.P. Plasma concentrations of the carboxyterminal propeptide of type I procollagen (PICP) in preterm neonates from birth to term. Pediatr. Res. 2000, 48:104-108.
122. Seki K., Furuya K., Makimura N., Mitsui C., Hirata J., Nagata I. Cord blood levels of calcium-regulating hormones and osteocalcin in premature infants. J.Perinatal Med. 1994, 22:189-194.
123. Seyedin S.M., Kung V.T., Daniloff Y.N., Hesley R.P., Gomez B., Nielsen L.A., Rosen H.N., Zuk R.F. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J.Bone Miner. Res. 1993, 8:635-641.
124. Shaw N.J., Dutton J., Fraser W.D., Smith C.S. Urinary pyridinoline and deoxypyridinoline excretion in children. Clin. Endocrinol. 1995, 42:607-612.
125. Shima M., Seino Y., Tanaka Y., Yabuuchi H., Tsutsumi C., Moriuchi S. Bone gamma-carboxyglutamic acid containing protein in the perinatal period. Acta Paediatr. Scand. 1985, 74:674-677.
126. Smedsrød B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 1990, 271:345-350.
127. Sorva A., Tähtelä R., Risteli J., Risteli L., Laitinen K., Juntu-Nen-Backman K., Sorva R. Familial high serum concentrations of the carboxy-terminal propeptide of type I procollagen. Clin. Chem. 1994, 40:1591-1593.
128. Sorva R., Kivivuori S.M., Turpeinen M., Marttinen E., Risteli J., Risteli L., Sorva A., Siimes M.A. Very low rate of type I collagen synthesis and degradation in newly diagnosed children with acute lymphoblastic leukemia. Bone 1997, 20:139-143.
129. Sorva R., Tahtela R., Turpeinen M., Juntunen-Backman K., Haahtela T., Risteli L., Risteli J., Sorva A. Changes in bone markers in children with asthma during inhaled and nedocromil treatments. Acta Paediatr. 1996, 85:1176-1180.
130. Sorva R., Turpeinen M., Juntunen-Backman K., Karonen S.L., Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J.Allergy Clin. Immunol. 1992, 90:808-815.
131. Spagnoli A., Branca F., Spadoni G.L., Cianfarani S., Pasquino A.M., Argiro G., Vitale S., Robins S.P., Boscherini B. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated w. J.Clin. Endocrinol Metab. 1996, 81:3589-3593.
132. Steinmann B., Eyre D.R., Shao P. Urinary pyridi-noline cross-links in Ehlers-Danlos syndrome type VI [Letter]. Am. J. Hum. Genet. 1995, 57:1505-1508.
133. Steinmann B., Royce P.M., Superti-Furga A. The Ehlers-Danlos syndrome. Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects 1993, 351-407. Wiley-Liss, Caldwell, NJ. P.M. Royce, B. Steinmann (Eds.).
134. Tanner J.M., Whitehouse R.H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child. 1976, 51:170-179.
135. Tietz N. Fundamentals of Clinical Chemistry 1976, 613-618. Saunders, New York.
136. Tillmann V., Gill M.S., Thalange N.K., Birkinshaw G., Price D.A., Fraser W.D., Clayton P.E. Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal children. Growth Horm. IGF Res. 2000, 10:28-36.
137. Tobiume H., Kanzaki S., Hida S., Ono T., Moriwake T., Yamauchi S., Tanaka H., Seino Y. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: A potential marker for bone formation an. J.Clin. Endocrinol. Metab. 1997, 82:2056-2061.
138. Tongsong T., Pongsatha S. Early prenatal sonographic diagnosis of congenital hypophosphatasia. Ultrasound Obstet. Gynecol 2000, 15:252-255.
139. Trivedi P., Risteli J., Risteli L., Hindmarsh P.C., Brook C.G.D., Mowat A.P. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children w. Pediatr. Res. 1991, 30:276-280.
140. Tsukahara H., Miura M., Hori C., Hiraoka M., Nosaka K., Hata K., Konishi Y., Sudo M. Urinary excretion of pyridinium cross-links of collagen in infancy. Metabolism 1996, 4:510-514.
141. Tsukahara H., Takeuchi M., Fujisawa K., Miura M., Hata K., Yamamoto K., Mayumi M. High-turnover osteopenia in preterm infants: Determination of urinary pyridinium crosslinks of collagen. Metabolism 1998, 47:333-335.
142. Urena P., Ferreira A., Kung V.T., Morieux C., Simon P., Ang K.S., Souberbielle J.C., Segre G.V., Drueke T.B., De Vernejoul M.C. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J.Bone Miner. Res. 1995, 10:932-939.
143. Vihervuori E., Turpeinen M., Siimes M.A., Koistinen H., Sorva R. Collagen formation and degradation increase during growth hormone in children. Bone 1997, 20:133-138.
144. Wharton B.A., Gough G., Williams A., Kitts S., Pennock C.A. Urinary total hydroxyproline:creatinine ratio. Arch. Dis. Child. 1972, 41:74.
145. Whyte M.P. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr. Rev. 1994, 15:439-461.
146. Widhalm K., Holzl M. Changes of alkaline phosphatase, inorganic phosphorus and total calcium in sera of 11 to 17 year old healthy adolescents, and their relationship to growth. J.Clin. Chem. Clin. Biochem. 1985, 23:711-717.
147. Yamaga A., Taga M., Hashimoto S., Ota C. Comparison of bone metabolic markers between maternal and cord blood. Horm. Res. 1999, 51:277-279.